Not for distribution to U.S. Newswire Services or for dissemination in the United States.
TORONTO, May 15, 2018 (GLOBE NEWSWIRE) — Adent Capital Corp. (NEX:ANT.H) (“Adent”) is pleased to announce that, further to its press release date May 7, 2018, a filing statement in respect of the qualifying transaction (the “Transaction”) involving Adent and Khiron Life Sciences Corp. (“Khiron”) has been prepared and filed in accordance with the requirements of the TSX Venture Exchange Inc. (“TSXV”) and posted under Adent’s issuer profile on SEDAR at www.sedar.com. Closing of the Transaction is expected to occur on or about May 16, 2018.
In connection with the Transaction and prior thereto, Adent will change its name to “Khiron Life Sciences Corp.” and consolidate its share capital on the basis of 8 (old) common shares for 1 (new) common share.
Khiron is a Canadian integrated medical cannabis company with its core operations in Colombia, and is fully licenced in Colombia for the cultivation, production, domestic distribution, and international export of both tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis. Khiron combines leading international scientific expertise, agricultural advantages, and branded product market entrance experience to address the unmet medical needs in a market of over 620 million people in Latin America.
Reference is also made to Adent’s press releases dated October 25, 2017, November 7, 2017, December 27, 2017 and January 16, 2018 for additional information relating to Adent, Khiron and the Transaction.
For additional information on the Transaction:
Chief Executive Officer
Direct: +1 (416) 459 9979
Completion of the Transaction is subject to a number of conditions including, but not limited to, TSXV acceptance and, if applicable, pursuant to policies of the TSXV, majority of the minority shareholder approval. There can be no assurance that the Transaction will be completed as proposed, or at all.
Investors are cautioned that, except as disclosed in the management information circular or filing statement to be prepared in connection with the Transaction, any information released or received with respect to the Transaction may not be accurate or complete and should not be relied upon. Trading in the securities of Adent should be considered highly speculative.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) has in any way passed upon the merits of the Transaction and associated transactions and neither of the foregoing entities has in any way approved or disapproved of the contents of this press release.
This news release contains “forward-looking information” within the meaning of applicable securities laws including statements regarding the terms and conditions of the Transaction, as well as information relating to Khiron. The information about Khiron contained in the press release has not been independently verified by Adent. Although Adent believes in light of the experience of its officers and directors, current conditions and expected future developments and other factors that have been considered appropriate, that the expectations reflected in this forward-looking information are reasonable, undue reliance should not be placed on them because Adent can give no assurance that they will prove to be correct. Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements depending on, among other things, the risks that the parties will not proceed with the Transaction; that the ultimate terms of the Transaction will differ from those that currently are contemplated; and that the Transaction will not be successfully completed for any reason (including the failure to obtain the required approvals or clearances from regulatory authorities). The terms and conditions of the Transaction may change based on Adent’s due diligence and the receipt of tax, corporate and securities law advice for both Adent and Khiron. The statements in this press release are made as of the date of this release. Adent undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of Adent, Khiron, their securities, or their respective financial or operating results (as applicable).